Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: Prognostic value of various measures

International Journal of Tuberculosis and Lung Disease

Volumn 6, Issue 1, 2002, Pages 3-10

  Tam, C M ^a   Chan, S L ^a   Kam, K M ^a   Goodall, R L ^a   Mitchison, D A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Age; Isoniazid; Relapse rates; Rifapentine; Sex; Tuberculosis

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RISK ASSESSMENT; SCHOOL CHILD; SIDE EFFECT; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; CHILD; DRUG THERAPY, COMBINATION; FEMALE; HONG KONG; HUMANS; ISONIAZID; LIFE TABLES; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PYRAZINAMIDE; RIFAMPIN; STREPTOMYCIN; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 0036199234     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis: Initial report
2. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Interim report: No activity of isoniazid in the continuation phase
3. Scientific blueprint for TB drug development
4. New antibacterial drugs for the treatment of mycobacterial disease in man
5. Development of rifapentine: The way ahead
6. Comparison of Chinese and Western rifapentines and improvement in bioavailability by prior taking of various meals
7. Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong
8. Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: Part I
9. TBTC Study 22 (Rifapentine trial): Preliminary results in HIV-negative patients
10. Application of DNA fingerprinting with IS986 to sequential mycobacterial isolates obtained from pulmonary tuberculosis patients in Hong Kong before, during and after short-course chemotherapy
11. Drug tolerance in Mycobacterium tuberculosis
12. Factors affecting relapse following short-course chemotherapy
13. A controlled comparison of two fully supervised once-weekly regimens in the treatment of newly diagnosed pulmonary tuberculosis
14. Controlled trial of intermittent regimens of rifampin plus isoniazid for pulmonary tuberculosis in Singapore. The results up to 30 months
15. Ethambutol plus isoniazid for the treatment of pulmonary tuberculosis - A controlled trial of four regimens
16. Low isoniazid (INH) levels are associated with TB treatment failure/relapse with once-weekly rifapentine (RPT) and INH